Passive Immunotherapy against HIV-1

Current Status and Potential
  • Joseph P. Cotropia
  • Kenneth E. Ugen
Part of the Infectious Agents and Pathogenesis book series (IAPA)


Acquire Immune Deficiency Syndrome Simian Immunodeficiency Virus Human Monoclonal Antibody Passive Immunization Passive Immunotherapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Robbins, J. B., Schneerson, R., and Szu, S. C., 1995, Perspective: Hypothesis: Serum IgG antibody is sufficient to confer protection against infectious diseases by inactivating the inoculum, J. Infect. Dis. 171:1387–1398.PubMedGoogle Scholar
  2. 2.
    Groothuis, J. R., Simoes, E. A. F., Levin, M. J., Hall, C. B., Long, C. E., Rodriguez, W. J., Arrobio, J., Meissner, H. C., Fulton, D. R., and Welliver, R. C., 1993, Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children, N. Engl. J. Med. 329:1524–1530.CrossRefPubMedGoogle Scholar
  3. 3.
    Santosham, M., Reid, R., Ambrosino, D. M., Wolff, M. C., Almeido-Hill, C., Moxon, R., Chir, B., and Siber, G. R., 1987, Prevention of Haemophilus influenza type b infections in high-risk infants treated with bacterial polysaccharide immune globulin, N. Engl. J. Med. 317:923–929.PubMedCrossRefGoogle Scholar
  4. 4.
    Shurin, P. A., Rehmus, J. M., Johnson, C. E., Marchant, C. D., Carlin, S. A., Super, D. M., van Hare, G. F., Jones, P. K, Ambrosino, D. M., and Siber, G. R., 1993, Bacterial polysaccharide immune globulin for prophylaxis of acute otitis media in high-risk children, J. Pediatr. 123:801–810.PubMedCrossRefGoogle Scholar
  5. 5.
    Hemming, V. G., Rodriguez, W., Kim, W. H., Brandt, C. D., Parrott, R. H., Burch, B., Prince, G. A., Baron, P. A., Fink, R. J., and Reaman, G., 1987, Intravenous immunoglobulin treatment of respiratory syncytial virus infections in infants and young children, Antimicrob. Agents Chemother. 31:1882–1886.PubMedGoogle Scholar
  6. 6.
    Beasley, R. P., Lin, C. C., Wang, K. Y., Hsieh, F. J., Hwang, L. Y., Stevens, C. E., Sun, T. S., and Szumuness, W., 1981, Hepatitis B immune globulin (HBIG) efficacy in the interruption of perinatal transmission of hepatitis B virus carrier state, Lancet 2:388–393.PubMedGoogle Scholar
  7. 7.
    Beasley, R. P., Hwang, L. Y., Stevens, C. E., Lin, C. C., Hsieh, F.J., Wang, K.Y., Sun, T. S., and Szmuness, W., 1983, Efficacy of hepatitis B immune globulin for prevention of perinatal transmission of the hepatitis B virus carrier state: Final report of a randomized double-blind, placebo-controlled trial, Hepatology 3:135–141.PubMedCrossRefGoogle Scholar
  8. 8.
    Krugman, S., 1994, Hepatitis B vaccine, in: Vaccines (S. A. Plotkin and E. A. Mortimer, eds.), Saunders, Philadelphia, pp. 419–438.Google Scholar
  9. 9.
    Gorny, M. R, Pinter, A., and Zolla-Pazner, S., 1989, Specific immunity to HIV and other retroviral infections, in: Progress in AIDS Pathology (H. Rotterdam and S. C. Sommers, eds.), Field and Wood, New York, pp. 181–199.Google Scholar
  10. 10.
    Zolla-Pazner, S., O’Leary, J., and Burda, S., 1995, Serotyping of primary human immuno-deficiency virus type 1 isolated from diverse geographic locations by flow cytometry, J. Virol. 69:3807–3815.PubMedGoogle Scholar
  11. 11.
    Tyler, D. S., Stanley, S. D., Zolla-Pazner, S., Gorny, M. R, Shadduck, P. P., Langlois, A. J., Matthews, T. J., Bolognesi, D. P., Palker, T. J., and Weinhold, K. J., 1990, Identification of sites within gp41 that serve as targets for antibodydependent cellular cytotoxicity by using human monoclonal antibodies, J. Immunol. 145:3276–3282.PubMedGoogle Scholar
  12. 12.
    Alsmadi, O., Herz, R., Pinter, A., and Tilley, S. A., 1997, A novel antibodydependent cellular cytotoxicity epitope in gp120 is identified by two monoclonal antibodies isolated from a long-term survivor of human immunodeficiency virus type 1 infection, J. Virol. 71:925–933.PubMedGoogle Scholar
  13. 13.
    Baum, L. L., Cassutt, K. J., and Knigge, R, 1996, HIV-1 gp120-specific antibody dependent cell-mediated cytotoxicity correlates with rate of disease progression, J. Immunol. 157:2168–2173.PubMedGoogle Scholar
  14. 14.
    Ljunggren, K., Moschese, V., Broliden, P.-A., Giaquinto, C., Quinti, I., Fenyő, E. M., Wahren, B., Rossi, P., and Jondal, M., 1990, Antibodies mediating cellular cytotoxicity and neutralization correlate with a better clinical stage in children born to human immunodeficiency virus-infected mothers, J. Infect. Dis. 161:198–202.PubMedGoogle Scholar
  15. 15.
    Zolla-Pazner, S., Gorny, M. R, Pinter, A., and Honnen, W., 1989, Reinterpretation of human immunodeficiency virus Western blot patterns, N. Engl. J. Med. 320:1280–1281.PubMedGoogle Scholar
  16. 16.
    Pinter, A., Honnen, W., and Tilley, S. A., 1989, Oligomeric structure of gp41, the transmembrane protein of HIV, J. Virol. 63:2674–2679.PubMedGoogle Scholar
  17. 17.
    Moore, J. P., Cao, Y., Qin, L., Sattentau, Q. J., Pyati, J., Koduri, R., Robinson, J., Barbas, C. R., Burton, D. R., and Ho, D. D., 1995, Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies, J. Virol. 69:101–109.PubMedGoogle Scholar
  18. 18.
    Javaherian, R, Langlois, A. J., McDanal, C., Ross, K. L., Eckler, L. I., Jellis, C. L., Profy, A. T., Rusche, J. R., Bolognesi, D. P., and Putney, S. D., 1989, Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein, Proc. Natl. Acad. Sci. USA 86:6768–6772.PubMedCrossRefGoogle Scholar
  19. 19.
    Javaherian, K., Langlois, A. J., LaRosa, G. J., Profy, A. T., Bolognesi, D. P., Helihy, W. C., Putney, S. D., and Matthews, T. J., 1990, Broadly neutralizing antibodies elicited by the hypervariable neutralizing determinant of HIV-1, Science 250:1590–1593.PubMedCrossRefGoogle Scholar
  20. 20.
    LaRosa, G. J., Weinhold, R, Profy, A. T., Langlois, A. J., Dreesman, G. R., Boswell, R. N., Shadduck, P., Bolognesi, D. P., Matthews, T. J., and Emini, E. A., 1991, Conserved sequence and structural elements in the HIV-1 principal neutralizing determinant: Further clarifications, Science 253:1146.PubMedCrossRefGoogle Scholar
  21. 21.
    Goudsmit, J., Meloen, R. H., and Brasseur, R., 1990, Map of sequential B cell epitopes of the HIV-1 transmembrane protein using human antibodies as probe, Intervirology 31:327–338.PubMedGoogle Scholar
  22. 22.
    Horal, P., Svennerholm, B., Jeansson, S., Rymo, L., Hall, W. W., and Vahlne, A., 1991, Continuous epitopes of the human immunodeficiencyvirus type I (HIV-I) transmembrane glycoprotein and reactivity of human sera to synthetic peptides representing various HIV-1 isolates, J. Virol. 65:2718–2723.PubMedGoogle Scholar
  23. 23.
    Vanini, S., Longhi, R., Lazzarin, A., Vigo, E., Siccardi, A. G., and Viale, G., 1993, Discrete regions of HIV-1 gp41 defined by syncytia-inhibiting affinity-purified human antibodies, AIDS 7:167–174.PubMedCrossRefGoogle Scholar
  24. 24.
    Xu, J. Y., Gorny, M. K., Palker, T., Karwowska, S., and Zolla-Pazner, S., 1991, Epitope mapping of two immunodominant domains of gp41, the transmembrane protein of human immunodeficiency virus type 1, using ten human monoclonal antibodies, J. Virol. 65:4832–4838.PubMedGoogle Scholar
  25. 25.
    Cotropia, J. P., Ugen, K. E., Kliks, S., Broliden, K., Broliden, P.-A., Hoxie, J. A., Srikantan, V., Williams, W. V., and Weiner, D. B., 1996, A human monoclonal antibody to HIV-1 gp41 with neutralizing activity against diverse laboratory isolates, J. Acquired Immune Defic. Syndr. Hum. Retorvirol. 12:221–232.Google Scholar
  26. 26.
    Cotropia, J., Ugen, K. E., Lambert, D., Ljunggrenn-Broliden, K., Kliks, S., Hoxie, J., and Weiner, D. B., Characterization of human monoclonal antibodies (HuMAb) to the HIV-1 transmembrane (TM) gp41 protein, in: Vaccines 92: Modern Approaches to New Vaccines Including Prevention of AIDS (F. Brown, R. M. Chanock, H. S. Ginsberg, and R. A. Lerner, eds.), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, pp. 157–163.Google Scholar
  27. 27.
    Kliks, S., Weiss, C., Cotropia, J., Katinger, H., and Levy, J., 1994, Synergism of broadly neutralizing effect by two transmembrane envelope gp41 HIV-1 monoclonal antibodies, presented at the Conference on Advances in AIDS Vaccine Development, Seventh Annual Meeting of the National Cooperative Vaccine Development Groups for AIDS (NCVDG), Reston, Virginia.Google Scholar
  28. 28.
    Muster, T., Guinea, R., and Trkola, A., 1994, Cross-neutralizing antibodies against divergent human immunodeficiencyvirus type 1 isolates induced by the gp41 sequence ELDKWAS, J. Virol. 68:4031–4034.PubMedGoogle Scholar
  29. 29.
    D’souza, M. P., Livnat, D., Bradac, J., Bridges, S., AIDS Clinical Trials Group, Antibody Selection Working Group and Investigators, 1997, Evaluation of monoclonal antibodies to human immunodeficiency virus type 1 primary isolates by neutralization assays: Performance criteria for selecting candidate antibodies for clinical trials, J. Infect. Dis. 175:1056–1062.PubMedGoogle Scholar
  30. 30.
    Cohen, J., 1993, Jitters jeopardize AIDS vaccine trials, Science 262:980–981.PubMedCrossRefGoogle Scholar
  31. 31.
    Mascola, J. R., Louwagie, J., McCutchan, F. E., Fischer, D. L., Hegerich, P. A., Wagner, K. F., Fowler, A. K., McNeil, J. G., and Burke, D. S., 1994, Two antigenically distinct subtypes of HIV-1; viral genotype predicts neutralization serotype, J. Infect. Dis. 169:48–54.PubMedGoogle Scholar
  32. 32.
    Matthews, T. J., 1994, The dilemma of neutralization resistance of HIV-1 field isolates and vaccine development, AIDS Res. Hum. Retrovir. 10:631–632.PubMedGoogle Scholar
  33. 33.
    Thali, M., Furman, C., Wahren, B., Posner, M., Ho, D. D., Robinson, J., and Sodroski, J., 1992, Cooperativity of neutralizing antibodies directed against the V3 and CD4 binding regions of the human immunodeficiency virus gp120 envelope glycoprotein, J. Acquired Immune Defic. Syndr. 5:591–599.Google Scholar
  34. 34.
    Tilley, S. A., Honnen, W. J., Racho, M. E., Chou, T. C., and Pinter, A., 1992, Synergistic neutralization of HIV-1 by human monoclonal antibodies against the V3 loop and the CD4 binding site of gp120, AIDS Res. Hum. Retrovir. 8:461–467.PubMedGoogle Scholar
  35. 35.
    Vijh-Warner, S., Pinter, A., Honnen, W. J., and Tilley, S. A., 1996, Synergistic neutralization of human immunodeficiency virus type 1 by a chimpanzee monoclonal antibody against the V2 domain of gp120 in combination with monoclonal antibodies against the V3 loop and the CD4-binding site, J. Virol. 70:4466–4473.Google Scholar
  36. 36.
    Li, A., Baba, T. W., Sodroski, J., Zolla-Pazner, S., Gorny, M. R, Robinson, J., Posner, M. R., Katinger, H., Barbas III, C. F., and Burton, D., 1997, Synergistic neutralization of a chimeric SIV/HIV type 1 virus with combinations of human anti-HIV type 1 envelope monoclonal antibodies or hyperimmune globulins, AIDS Res. Hum. Retrovir. 13:647–656.PubMedGoogle Scholar
  37. 37.
    Hioe, C. E., Xu, S., Chigurupati, P., Burda, S., Williams, C., Gorny, M. R, and Zolla-Pazner, S., 1997, Neutralization of HIV-1 primary isolates by polyclonal and monoclonal human antibodies, Int. Immunol. 9:1281–1290.CrossRefPubMedGoogle Scholar
  38. 38.
    Broliden, P. A., Moschese, V., Ljunggren, R, Rosen, J., Fundaro, C., Plebani, A., Jondal, M., Rossi, P., and Wahren, B., 1989, Diagnostic implication of specific immunoglobulin G patterns of children born to HIV-infected mothers, AIDS 3:577–582.PubMedCrossRefGoogle Scholar
  39. 39.
    Goedert, J., Mendez, H., Drummond, J., Robert-Guroff, M., Minkoff, H., Holman, S., Stevens, R., Rubinstein, A., Blattner, W., and Willoughby, A., 1989, Mother-to-infant transmission of human immunodeficiencyvirus type 1: Association with prematurity or low anti-gp120, Lancet 2:1351–1354.PubMedCrossRefGoogle Scholar
  40. 40.
    Rossi, P., Moschese, V., Broliden, P., Fundaro, C., Quinti, I., Plebani, A., Giaquinto, C., Tovo, P., Ljunggren, K, and Rosen, J., 1989, Presence of maternal antibodies to human immunodeficiency virus 1 envelope glycoprotein gp120 epitopes correlates with the uninfected status of children born to seropositive mothers, Proc. Natl. Acad. Sci. USA 86:8055–8058.PubMedCrossRefGoogle Scholar
  41. 41.
    Devash, Y., Calvelli, T., Wood, D., Reagan, K, and Rubinstein, A., 1990, Vertical transmission of human immunodeficiency virus is correlated with the absence of high-affinity/avidity maternal antibodies to the gp120 principal neutralizing domain, Proc. Natl. Acad. Sci. USA 87:3445–3449.PubMedCrossRefGoogle Scholar
  42. 42.
    Goedert, J. J., and Dublin, S., 1994, Perinatal transmission of HIV type 1: Associations with maternal anti-HIV serological reactivity, AIDS Res. Hum. Retrovir. 10:1125–1134.PubMedGoogle Scholar
  43. 43.
    Ugen, K. E., Goedert, J. J., Boyer, J., Refaeli, Y., Frank, I., Williams, W. V., Willoughby, A., Landesman, S., Mendez, H., and Rubinstein, A., 1992, Vertical transmission of human immunodeficiency virus (HIV) infection. Reactivity of maternal sera with glycoprotein 120 and 41 peptides from HIV type 1, J. Clin. Invest. 89:1923–1930.PubMedCrossRefGoogle Scholar
  44. 44.
    Ugen, K. E., Srikantan, V., Goedert, J. J., Nelson, R. P., Williams, W. V., and Weiner, D. B., 1997, Vertical transmission of the human immunodeficiency virus type 1: Seroreactivity by maternal antibodies to the carboxy region of the gp41 envelope glycoprotein, J. Infect. Dis. 175:63–69.PubMedGoogle Scholar
  45. 45.
    Loomis-Price, L. D., Cox, J. H., Mascola, J. R., VanCott, T. C., Michael, N. L., Fouts, T. R., Redfield, R. R., Robb, M. L., Wahren, B., and Sheppard, H. W., 1998, Correlation between humoral responses to human immunodeficiencyvirus type 1 envelope and disease progression in early-stage infection, J. Infect. Dis. 178:1306–1316.CrossRefPubMedGoogle Scholar
  46. 46.
    Boyer, J. D., Ugen, K. E., Chattergoon, M., Wang, B., Shah, A., Agadjanyan, M., Bagarazzi, M., Javadian, A., Carrano, R., and Coney, L., 1997, DNA vaccination as anti-human immunodeficiency virus immunotherapy in infected chimpanzees, J. Infect. Dis. 176:1501–1509.PubMedCrossRefGoogle Scholar
  47. 47.
    Geffin, R., Scott, G. B., Melenwicki, M., Hutto, C., Lai, S., Boots, L. J., McKenna, P., Kessler, J. A., and Conley, A. J., 1998, Association of antibody reactivity to ELDKWA, a glycoprotein 41 neutralization epitope, with disease progression in children perinatally infected with HIV type 1, AIDS Res. Hum. Retrovir. 14:579–590.PubMedGoogle Scholar
  48. 48.
    Jackson, G. G., Rubenis, M., Knigge, M., Perkins, J. T., Paul, D. A., Despotes, J. C., and Spencer, P., 1988, Passive immunoneutralisation of human immunodeficiency virus in patients with advanced AIDS, Lancet ii:647–652.CrossRefGoogle Scholar
  49. 49.
    Karpas, A., Hill, F., Youle, M., Cullen, V., Gray, J., Byron, N., Hayhoe, F., Tenant-Flowers, M., Howard, L., and Gilgen, D., 1988, Effects of passive immunization in patients with the acquired immunodeficiency syndrome-related complex and acquired immunodeficiency syndrome, Proc. Natl. Acad. Sci. USA 85:9234–9237.PubMedCrossRefGoogle Scholar
  50. 50.
    Jacobson, J. M., Colman, N., and Ostrow, N. A., 1993, Passive immunotherapy in the treatment of advanced HIV infection, J. Infect. Dis. 168:298–305.PubMedGoogle Scholar
  51. 51.
    Karpas, A., 1994, Passive immunotherapy in treatment of advanced HIV infection, J. Infect. Dis. 170:742–744.PubMedGoogle Scholar
  52. 52.
    Levy, J., Youvan, T., Lee, M. L., and Group, P. H. T. S., 1994, Passive hyperimmune plasma therapy in the treatment of acquired immunodeficiency syndrome: Results of a 12 month multicenter double-blind controlled trial, Blood 84:2130–2135.PubMedGoogle Scholar
  53. 53.
    Vittecoq, D., Chevret, S., and Morand-Joubert, L., 1995, Passive immunotherapy in AIDS: A double-blind randomized study based on transfusion of plasma rich in anti-HIV-1 antibodies vs transfusion of seronegative plasma, Proc. Natl. Acad. Sci. USA 92:1195–1199.PubMedCrossRefGoogle Scholar
  54. 54.
    Van Rompay, K. K., Berardi, C. J., Dillard-Telm, S., P., T. R., Canfield, D. R., Valverde, C. R., Montefiori, D. C., Cole, K. S., Montelaro, R. C., and Miller, C. J., 1998, Passive immunization of newborn rhesus macaques prevents oral simian immunodeficiency virus infection, J. Infect. Dis. 177:1247–1259.PubMedGoogle Scholar
  55. 55.
    Emini, E., 1989, Neutralization of in vivo HlV-1 infectivity mediated by in vitro neutralizing antibody, in: VInternational Conference on AIDS, Montreal, Canada, p. 538.Google Scholar
  56. 56.
    Emini, E. A., Nara, P. L., Schleif, W. A., Lewis, J. A., Davide, J. P., Lee, D. R., Kessler, J., Conley, S., Matsushita, S., and Putney, S. D., 1990, Antibody-mediated in vitroneutralization of human immunodeficiency virus type 1 abolishes infectivity for chimpanzees, J. Virol. 64:3674–3678.PubMedGoogle Scholar
  57. 57.
    Prince, A. M., Reesink, H., and Pascual, D., 1991, Prevention of HlV infection by passive immunization with HIV immunoglobulin, AIDS Res. Hum. Retrovir. 7:971–973.PubMedGoogle Scholar
  58. 58.
    Emini, A. E., Schleif, W. A., Nunberg, J. H., Conley, A. J., Eda, Y., Tokiyoshe, S., Putney, S. D., Matsushita, S., Cobb, K. E., and Jett, C. M., 1992, Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody, Nature 355:728–730.CrossRefPubMedGoogle Scholar
  59. 59.
    Conley, A. J., Kessler, J. A., Boots, L., McKenna, P. M., Schleif, W., Emini, E., Mark, G., Katinger, H., Cobb, E. K., and Lunceford, S. M., 1996, The consequence of passive administration of an anti-human immunodeficiency virus type 1 neutralizing antibody before challenge of chimpanzees with a primary isolate, J. Virol. 70:6751–6758.PubMedGoogle Scholar
  60. 60.
    Hinkula, J., Bratt, G., Gilljam, G., Nordlund, S., Broliden, P.-A., Holmberg, V., Olausson-Hansson, E., Albert, J., Sandströrm, E., and Wahren, B., 1994, Immunological and virological interactions in patients receiving passive immunotherapy with HIV-1 neutralizing monoclonal antibodies, J. Acquired Immune Defic. Syndr 7:940–951.Google Scholar
  61. 61.
    Gtinthard, H., Gowland, P. L., Schtipback, J., Fund, M. S. C., Böni, J., Liou, R.-S., Chang, N. T., Grob, P., Graepel, P., Braun, D. G., and Lüthy, R., 1994, Aphase I/IIA clinical study with a chimeric mouse-human monoclonal antibody to the V3 loop of human immunodeficiency virus type 1 gp120, J. Infect. Dis. 170:1384–1393.Google Scholar
  62. 62.
    Katinger, H., Purtscher, M., Muster, T., Steindl, F., Dopper, S., Vetter, N., Armbruster, C., and Gelbmann, H., 1995, A small phase I clinical trial with the human anti-Hiv-1 mAb 2F5, in: Dixieme Colloque des Cent Gardes, pp. 291–297.Google Scholar
  63. 63.
    Cavacini, L. A., Samore, M. H., Gambertoglio, J., Jackson, B., Duval, M., Wisnewski, A., Hammer, S., Koziel, C., Trapnell, C., and Posner, M. R., 1998, Phase I study of a human monoclonal antibody directed against the CD4-binding site of HIV type 1 glycoprotein 120, AIDS Res. Hum. Retrovir. 14545–550.Google Scholar
  64. 64.
    Safrit, J. T., Fung, M., Andrews, C., Braun, D., Sun, W., Chang, T. W., and Koup, R. A., 1993, hu-PBL-SCID mice can be protected from HIV-1 infection by passive transfer of monoclonal antibody to the principal neutralizing determinant of envelope gp120, AIDS 7:15–21.PubMedCrossRefGoogle Scholar
  65. 65.
    Gauduin, M.-C., Jeffrey, S., Weir, R., Fung, M. S. C., and Koup, R. A., 1995, Pre-and postexposure protection against human immunodeficiency virus type 1 infection mediated by a monoclonal antibody, J. Infect. Dis. 171:1203–1209.PubMedGoogle Scholar
  66. 66.
    Parren, P. W. H. I., Ditzel, H. J., Gulizia, R. J., Binley, J. M., Barbas III, C. F., Burton, D. R., and Mosier, D. E., 1995, Protection against HIV-1 infection in hu-BPBL-SCID mice by passive immunization with a neutralizing human monoclonal antibody against the gp120 CD4-binding site, AIDS 9:F1–F6.PubMedCrossRefGoogle Scholar
  67. 67.
    Andrus, L., Prince, A. M., Bernal, I., McCormack, P., Lee, D.-H., Gorny, M. K., and Zolla-Pazner, S., 1998, Passive immunization with a human immunodeficiency virus type 1-neutralizing monoclonal antibody in hu-PBL-SCID mice: Isolation of a neutralization escape variant, J. Infect. Dis. 177:889–897.PubMedGoogle Scholar
  68. 68.
    Poignard, P., Gulizia, R. J., Picchio, G., Wang, M., Parren, P. W. H., Mosier, D. E., and Burton, D. R., 1998, Study of the impact of neutralizing antibodies on the course of established infection with HIV-1 primary isolates in the hu-PBL-SClD mouse model, presented at the XIIth World AIDS Conference, Geneva, Switzerland.Google Scholar
  69. 69.
    Koup, R. A., Hesselton, R. M., Safrit, J. T., Somasundaran, M., and Sullivan, J. L., 1994, Quantitative assessment of human immunodeficiency virus type 1 replication in human xenografts of acutely-infected hu-PBL-SCID mice, AIDS Res. Hum. Retrovir. 10:279–284.PubMedGoogle Scholar
  70. 70.
    Hesselton, R. M., Koup, R. A., Cromwell, M. A., Graham, B. S., Johns, M., and Sullivan, J. L., 1993, Human peripheral blood xenografts in the SCID mouse: Characterization of immunologic reconstitution, J. Infect. Dis. 168:630–640.PubMedGoogle Scholar
  71. 71.
    Robinson, W. E., Kawamura, T., Gorny, M. R, Lake, D., Xu, J.-Y., Matsumoto, Y., Sugan, T., Masuho, Y., Mitchell, W. M., and Hersh, E. M., 1990, Human monoclonal antibodies to the human immunodeficiency virus type 1 (HIV-1) transmembrane glycoprotein gp41 enhance HIV-1 infection in vitro, Proc. Natl. Acad. Sci. USA 87:3185–3189.PubMedCrossRefGoogle Scholar
  72. 72.
    Robinson, W. E., Kawamura, T., Lake, D., Masuho, Y., Mitchell, W. M., and Hersh, E. M., 1990, Antibodies to the primary immunodominant domain of human immunodeficiency virus type 1 (HIV-1) glycoprotein gp41 enhance HIV-1 infection in vitro, J. Virol. 64:5301–5305.PubMedGoogle Scholar
  73. 73.
    Eaton, A. M., Ugen, K. E., Weiner, D. B., Wildes, T., and Levy, J. A., 1994, An anti-gp41 human monoclonal antibody that enhances HIV-1 infection in the absence of complement, AIDS Res. Hum. Retrovir. 10:13–18.PubMedGoogle Scholar
  74. 74.
    Bugge, T. H., Lindhardt, B. O., Hansen, L. L., Kusk, P., Hulgaard, E., Holmback, K., Klasse, P. J., Zeuthen, J., and Ulrich, R, 1990, Analysis of a highly immunodominant epitope in the human immunodeficiency virus type 1 transmembrane glycoprotein gp41, defined by a human monoclonal antibody, J. Virol. 64:4123–4129.PubMedGoogle Scholar
  75. 75.
    Cavacini, L. A., Emes, C. L., Wisnewski, A. V., Power, J., Lewis, G., Montefiori, D., and Posner, M. R., 1998, Functional and molecular characterization of human monoclonal antibody reactive with the immunodominant region of HIV type 1 glycoprotein 41, AIDS Res.Hum.Retrovir.14:1271–1280.PubMedGoogle Scholar
  76. 76.
    Burton, D. R., Pyati, J., Koduri, R., Sharp, S. J., Thornton, G. B., Parren, P. W. H. I., Sawyer, L. S. W., Hendry, M., Dunlop, N., and Nara, P. L., 1994, Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody, Science 266:1024–1027.PubMedCrossRefGoogle Scholar
  77. 77.
    Roben, P., Moore, J. P., Thali, M., Sodroski, J., Barbas 111, C. F., and Burton, D. R., 1994, Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing ab es to neutralize human immunodeficiency virus type 1, J. Virol. 68:4821–4828.PubMedGoogle Scholar
  78. 78.
    Trkola, A., Purtscher, M., Muster, T., Ballaun, C., Buchacher, A., Sullivan, N., Srinivasan, R, Sodroski, J., Moore, J. P., and Katinger, H., 1996, Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1, J. Virol. 70:1100–1108.PubMedGoogle Scholar
  79. 79.
    Buchacher, A., Predl, R., Strutzenberger, R, Steinfellner, W., Trkola, A., Purtscher, M., Gruber, G., Tauer, C., Steindl, F., and Jungbauer, A., 1994, Generation of human monoclonal antibodies against HIV-1 proteins; Electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization, AIDS Res. Hum. Retrovir. 10: 359–369.PubMedCrossRefGoogle Scholar
  80. 80.
    Conley, A. J., Kessler II, J. A., Boots, L.J., Tung, J.-S., Arnold, B. A., Keller, P. M., Shaw, A. R., and Emini, E. A., 1994, Neutralization of divergent human immunodeficiency virus type 1 variants and primary isolates by IAM-41-2F5, an anti-gp41 human monoclonal antibody, Proc. Natl. Acad. Sci. USA 91:3348–3352.PubMedCrossRefGoogle Scholar

Copyright information

© Kluwer Academic Publishers 2002

Authors and Affiliations

  • Joseph P. Cotropia
    • 1
    • 2
  • Kenneth E. Ugen
    • 3
  1. 1.BioClonetics, Inc.Philadelphia
  2. 2.Department of MedicineUniversity of Pennsylvania School of MedicinePhiladelphia
  3. 3.Department of Medical Microbiology and ImmunologyUniversity of South Florida College of MedicineTampa

Personalised recommendations